domperidone has been researched along with Impotence in 2 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " New dopamine D4 receptor agonists, exemplified by (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (59a) and (E)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (64a), exhibited favorable pharmacokinetic profiles and showed oral bioavailability in rat and dog." | 1.33 | 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. ( Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM, 2006) |
| "The goal of this study was to identify a structurally distinct D(4)-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction." | 1.33 | Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ( Brioni, JD; Chang, R; Cowart, MD; Darbyshire, JF; Donnelly-Roberts, DL; El-Kouhen, OF; Gintant, G; Hakeem, AA; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martin, R; Martino, BR; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Nelson, SL; Patel, MV; Rohde, JJ; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME; Wetter, JM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolasa, T | 2 |
| Matulenko, MA | 2 |
| Hakeem, AA | 2 |
| Patel, MV | 2 |
| Mortell, K | 2 |
| Bhatia, P | 1 |
| Henry, R | 1 |
| Nakane, M | 2 |
| Hsieh, GC | 2 |
| Terranova, MA | 2 |
| Uchic, ME | 2 |
| Miller, LN | 2 |
| Chang, R | 2 |
| Donnelly-Roberts, DL | 2 |
| Namovic, MT | 2 |
| Hollingsworth, PR | 2 |
| Martino, B | 1 |
| El Kouhen, O | 1 |
| Marsh, KC | 2 |
| Wetter, JM | 2 |
| Moreland, RB | 2 |
| Brioni, JD | 2 |
| Stewart, AO | 2 |
| Rohde, JJ | 1 |
| Nelson, SL | 1 |
| Cowart, MD | 1 |
| El-Kouhen, OF | 1 |
| Martino, BR | 1 |
| Martin, R | 1 |
| Darbyshire, JF | 1 |
| Gintant, G | 1 |
| Sullivan, JP | 1 |
2 other studies available for domperidone and Impotence
| Article | Year |
|---|---|
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug | 2006 |
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Topics: Action Potentials; Administration, Oral; Animals; Benzamides; Biological Availability; Cell Line; Cy | 2006 |